MADISON, N.J., June 9, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that, in light of recent progress in finalizing its clinical trials joint venture, Mark Guinan, the company's Senior Vice President and CFO, will provide commentary on its revenue outlook when he presents at the Goldman Sachs 2015 Global Healthcare Conference in Rancho Palos Verdes, California on June 10.
On March 31, 2015, Quest announced its plan to form a global clinical trials joint venture. Based on recent progress, the joint venture is now expected to close in early July.
The presentation is scheduled for Wednesday, June 10, 2015 at 2:20 p.m. Eastern Daylight Time. It will be webcast live during the conference and will be available to registered investors on the following site: http://cc.talkpoint.com/gold006/060915a_ae/?entity=62_ULYG5F2 and to the public on www.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until July 10, 2015.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
CONTACTS: Dan Haemmerle (investors) at 973-520-2900 and Dennis Moynihan (media) at 973-520-2800.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/quest-diagnostics-to-comment-on-2015-revenue-outlook-in-light-of-joint-venture-progress-at-goldman-sachs-36th-annual-global-healthcare-conference-300096008.html
SOURCE Quest Diagnostics Incorporated